Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 6
2006 2
2007 3
2009 6
2010 2
2011 8
2012 4
2013 13
2014 5
2015 9
2016 14
2017 14
2018 15
2019 13
2020 24
2021 22
2022 24
2023 22
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for luo yi shi
Search for Luoyi Shi instead (3 results)
Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 Edition).
Zeng XT, Jin YH, Liu TZ, Chen FM, Ding DG, Fu M, Gu XQ, Han BM, Huang X, Hou Z, Hu WL, Kang XL, Li GH, Li JX, Li PJ, Liang CZ, Liu XH, Liu ZY, Liu CX, Liu JM, Luo GH, Luo Y, Qin WJ, Qiu JH, Qiu JX, Shang XJ, Shi BK, Sun F, Tian GX, Tian Y, Wang F, Wang F, Wang YH, Wang YJ, Wang ZP, Wang Z, Wei Q, Xiao MH, Xu WH, Yi FX, Zhu CY, Zhuang QY, Zhou LQ, Zou XF, Xing NZ, He DL, Wang XH; Chinese Urological Doctor Association (CUDA); Urological Association of Chinese Research Hospital Association (CRHA-UA); Uro-Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (CPAM-UHPA). Zeng XT, et al. Among authors: luo y. Mil Med Res. 2022 Apr 1;9(1):14. doi: 10.1186/s40779-022-00371-6. Mil Med Res. 2022. PMID: 35361280 Free PMC article.
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, Yu H, Zhao Y, Chen W, Luo Y, Wu L, Wang X, Pirker R, Nan K, Jin F, Dong J, Li B, Sun Y. Han B, et al. Among authors: luo y. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039. JAMA Oncol. 2018. PMID: 30098152 Free PMC article. Clinical Trial.
The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma.
He Y, Zhan L, Shi J, Xiao M, Zuo R, Wang C, Liu Z, Gong W, Chen L, Luo Y, Zhang S, Wang Y, Chen L, Guo H. He Y, et al. Among authors: luo y. Adv Sci (Weinh). 2023 Jun;10(18):e2207650. doi: 10.1002/advs.202207650. Epub 2023 Apr 21. Adv Sci (Weinh). 2023. PMID: 37083239 Free PMC article.
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study.
Shao R, Zhang Y, He J, Huang F, Fan Z, Yang K, Xu Y, Xu N, Luo Y, Deng L, Zhang X, Chen J, Han M, Li X, Yu S, Liu H, Liang X, Luo X, Shi P, Wang Z, Jiang L, Zhou X, Lin R, Chen Y, Tu S, Sun J, Wang Y, Liu Q, Xuan L. Shao R, et al. Among authors: luo y. Signal Transduct Target Ther. 2023 Sep 14;8(1):348. doi: 10.1038/s41392-023-01614-1. Signal Transduct Target Ther. 2023. PMID: 37704613 Free PMC article.
The combined effect of metformin and mirabegron on diet-induced obesity.
Zhao XY, Liu Y, Zhang X, Zhao BC, Burley G, Yang ZC, Luo Y, Li AQ, Zhang RX, Liu ZY, Shi YC, Wang QP. Zhao XY, et al. Among authors: luo y. MedComm (2020). 2023 Feb 14;4(2):e207. doi: 10.1002/mco2.207. eCollection 2023 Apr. MedComm (2020). 2023. PMID: 36818016 Free PMC article.
199 results